Table 1 Baseline characteristics of the study population. Data are presented as mean ± sd unless otherwise stated
Variable | All patients (N = 263) | Patients with antifibrotic (N = 132) | Patients without treatment (N = 131) | p-value |
|---|---|---|---|---|
Age at diagnosis(years) | 70.4 ± 8.8 | 68.3 ± 7.8 | 72.5 ± 9.3 | 0.0002 |
50–65 years N (%) | 47 (19.8%) | 31 (27%) | 16 (13.1%) | < 0.0001 |
66–75 years N (%) | 107 (45.2%) | 60 (52.2%) | 47 (38.5%) | |
> 75 years N (%) | 83 (35.0%) | 24 (20.9%) | 59 (48.4%) | |
Gender | 0.21 | |||
Male N (%) | 182 (69.2%) | 96(72.7%) | 86 (65.7%) | |
Female N (%) | 81 (30.8%) | 36 (27.3%) | 45 (34.4%) | |
BMI (kg/m2) median | 27.8 (25.5,30.8) | 28.0 (25.3–30.9) | 27.8 (25.6–30.3) | 0.91 |
FVC (% of predicted) | 83.0 ± 17.4 | 77.3 ± 14.8 | 88.1 ± 17.9 | < 0.001 |
FVC ≤ 75% N (%) | 69 (33.7%) | 42 (43.3%) 55 (56.7%) | 27 (25%) | 0.0056 |
FVC > 75% N (%) | 136 (66.3%) | 81 (75%) | ||
DLCO/VA (% of predicted) | 62.2 ± 14.7 | 59.5 ± 14.2 | 64.3 ± 14.9 | 0.022 |
DLCO/VA ≤ 55 N (%) | 66 (33.7%) | 36(40.9%) | 30(27.8%) | 0.053 |
DLCO/VA > 55 N (%) | 130 (66.3%) | 52 (59.1%) | 78 (72.2%) | |
Smoking at diagnosis | 0.93 | |||
Never smoker N (%) | 96 (37.7%) | 46 (36.5%) | 50 (38.8%) | |
Current smoker N (%) | 20 (7.8%) | 10 (7.9%) | 10 (7.8%) | |
Ex-smoker N (%) | 139 (54.5%) | 70 (55.6%) | 69 (53.5%) | |
Number of medications at diagnosis (other than antifibrotic) median | 5(1,9) | 5 (1,9) | 6.0 (2.0,9.0) | 0.65 |
0–1 medications N (%) | 66 (25.1%) | 34 (25.8%) | 32 (24.4%) | 0.90 |
2–4 medications N (%) | 40 (15.2%) | 21 (15.9%) | 19 (14.5%) | |
≥ 5 medications N (%) | 157 (59.7%) | 77 (58.3%) | 80 (61.1%) |